<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neuroendocrine neoplasms of unknown primary site</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neuroendocrine neoplasms of unknown primary site</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neuroendocrine neoplasms of unknown primary site</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John D Hainsworth, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">F Anthony Greco, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan R Strosberg, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James R Jett, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 24, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cancer of unknown primary site (CUP) accounts for approximately 2 percent of all invasive cancers [<a href="#rid1">1</a>]. Within this category, tumors from many primary sites with varying biology are represented. Neuroendocrine neoplasms (NENs) constitute less than 5 percent of all CUPs [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/4878.html" rel="external">"Overview of the classification and management of cancers of unknown primary site"</a>.)</p><p>NENs are a heterogeneous group of neoplasms that differ in biologic behavior, histologic appearance, and response to treatment  (<a class="graphic graphic_table graphicRef76723" href="/z/d/graphic/76723.html" rel="external">table 1</a>). Several types of these neoplasms (eg, well-differentiated neuroendocrine tumors (NETs) of the tubular gastrointestinal tract [previously referred to as carcinoid tumors] and pancreas [pancreatic NETs or PNETs], medullary thyroid cancers, pheochromocytomas) are characterized by slow growth and frequent secretion of hormones or vasoactive substances [<a href="#rid3">3-5</a>]. In most cases, these tumors also have typical histologic appearance and are accurately diagnosed with standard pathologic methods (light microscopy and immunohistochemical staining). Others, as typified by small cell carcinoma of the lung, are highly aggressive neoplasms, classified as neuroendocrine carcinomas (NECs), and are usually advanced when diagnosed. (See  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system"</a>.)</p><p>This review will cover the evaluation and treatment of patients with biopsy-proven metastatic NENs of unknown primary. The diagnostic workup of rare patients who present with symptoms suggestive of an underlying neuroendocrine hormonal syndrome (eg, flushing, diarrhea, hypoglycemia, hyperglycemia) is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2622.html" rel="external">"Diagnosis of carcinoid syndrome and tumor localization"</a> and  <a class="medical medical_review" href="/z/d/html/2612.html" rel="external">"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms", section on 'Functionality and nomenclature'</a>.) </p><p class="headingAnchor" id="H3101827305"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Neuroendocrine neoplasms (NENs) of unknown primary site are relatively uncommon, accounting for 10 to 14 percent of all NENs:</p><p class="bulletIndent1"><span class="glyph">●</span>In a review of over 35,000 patients diagnosed with NENs over a 31-year period (most had well-differentiated tumors arising from the gastrointestinal tract), a primary site could not be found or classified in only 13 percent [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another series of 750 patients with NENs seen over a 24-year period at a single institution, 82 (10 percent) were of unknown primary site [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective one-year survey among French pathologists (the PRONET study), 190 of 1340 cases of NENs (14 percent) were classified as NENs with an unknown primary site [<a href="#rid8">8</a>]. Ninety-one (48 percent) were well differentiated, five were moderately differentiated, and 84 (44 percent) were poorly differentiated.</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PATHOLOGIC CLASSIFICATION</span><span class="headingEndMark"> — </span>Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies. Clinical behavior and prognosis correlate closely with histologic differentiation and grade. The World Health Organization (WHO) classifies well-differentiated gastroenteropancreatic NETs into low-grade (G1), intermediate-grade (G2), and high-grade (G3) categories based on histologic appearance and proliferative rate (as assessed by mitotic count and/or Ki-67 labeling index)  (<a class="graphic graphic_table graphicRef122325" href="/z/d/graphic/122325.html" rel="external">table 2</a>) [<a href="#rid9">9</a>]. Many well-differentiated G1 or G2 NETs have a generally indolent clinical behavior. All poorly differentiated neuroendocrine neoplasms (NENs) are G3 neuroendocrine carcinomas (NECs), with an aggressive clinical course. The clinical behavior of the small subset of well-differentiated NETs that have a high proliferative rate (NET, G3) is midway between these two entities. This uniform grading scheme applies to unknown primary site tumors unless a different primary site (eg, the lung) is found [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Classification and terminology'</a> and  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms", section on 'High-grade, well-differentiated tumors (NET G3)'</a>.)</p><p>Poorly differentiated NECs are often widely metastatic, and they rarely produce symptoms related to secretion of bioactive substances. Some of these have a histology similar to small cell carcinoma of the lung; a large cell neuroendocrine variant also exists. Some poorly differentiated NECs lack morphologic features of neuroendocrine differentiation [<a href="#rid10">10</a>]. Diagnosis of these cancers depends on immunohistochemical staining for chromogranin and/or synaptophysin. (See  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms", section on 'Pathologic diagnosis'</a>.)</p><p>Accurate distinction of well-differentiated, indolent tumors from poorly differentiated, aggressive tumors and well-differentiated, G3 tumors is important since treatment approaches are different. (See <a class="local">'Evaluation and management'</a> below.)</p><p class="headingAnchor" id="H2332174589"><span class="h1">CLINICAL PRESENTATION AND PRIMARY SITES</span><span class="headingEndMark"> — </span>NENs of unknown primary site, especially well-differentiated NETs, often present initially with liver metastases, and most (but not all) represent gastroenteropancreatic NETs [<a href="#rid11">11</a>]. In some patients, the primary site is subsequently identified in the intestinal tract or the pancreas. Patients with mesenteric masses on imaging scans and no evidence of disease on upper or lower endoscopy can be considered to have small intestinal primary tumors and should be treated according to guidelines for small intestinal NETs.</p><p>Just as immunohistochemistry and molecular cancer classifier assay (MCCA) can aid in identifying a tumor as having a neuroendocrine origin, these tests may also help to localize the site of origin [<a href="#rid12">12-14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><em>TTF-1</em> is expressed in most poorly differentiated NECs and some well-differentiated NETs of lung origin. However, an important caveat is that <em>TTF-1</em> expression can also be detected in other extrapulmonary poorly differentiated NECs [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>CDX2</em> may be expressed in well-differentiated NETs of intestinal origin [<a href="#rid16">16,17</a>]; it may also be found in poorly differentiated lung NECs, especially in the large cell subtype [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Expression of <em>ISL1</em> is commonly considered a marker of pancreatic origin, although it may be expressed in extrapancreatic poorly differentiated NECs [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positivity for <em>PAX8</em> or <em>ISL1</em> suggests pancreatic, duodenal, or rectal origin [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 92-gene MCCA is quite accurate in the diagnosis of specific NENs [<a href="#rid14">14</a>]; however, some NENs have gene expression patterns that overlap, and a specific diagnosis cannot be made.</p><p></p><p>Although immunohistochemistry stains and a MCCA often aid in the diagnosis of the likely site of origin of a NEN it is important to remember that none of the immunohistochemistry stains listed above is definitive, and a MCCA may suggest several NENs as diagnostic possibilities.</p><p>A more detailed discussion of the pathology and classification of NENs arising in the digestive tract and lung is available elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system"</a> and  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a> and  <a class="medical medical_review" href="/z/d/html/4603.html" rel="external">"Pathology of lung malignancies", section on 'Neuroendocrine tumors'</a>.)</p><p class="headingAnchor" id="H7120407"><span class="h1">EVALUATION AND MANAGEMENT</span><span class="headingEndMark"> — </span>The following sections will describe evaluation and management based on the histologic pattern and clinical features of neuroendocrine neoplasms (NENs) of unknown primary site.</p><p class="headingAnchor" id="H3"><span class="h2">Well-differentiated neuroendocrine tumor</span><span class="headingEndMark"> — </span>Patients with well-differentiated neuroendocrine tumors (NETs) of unknown primary site usually have liver metastases, and clinical syndromes from tumor production of bioactive substances may be apparent [<a href="#rid7">7</a>]. The presence of carcinoid syndrome usually suggests a small intestinal primary NET, although pancreatic and lung NETs can occasionally secrete serotonin and other vasoactive substances associated with carcinoid syndrome. (See  <a class="medical medical_review" href="/z/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome", section on 'Frequency'</a>.)</p><p class="headingAnchor" id="H1146371"><span class="h3">Initial workup</span><span class="headingEndMark"> — </span>The initial evaluation should include cross-sectional imaging, somatostatin receptor imaging (preferably with a <a class="drug drug_general" data-topicid="108440" href="/z/d/drug information/108440.html" rel="external">gallium Ga-68 DOTATATE</a> [Ga-68 DOTATATE], Ga-68 DOTATOC, or <a class="drug drug_general" data-topicid="129471" href="/z/d/drug information/129471.html" rel="external">copper Cu-64 DOTATATE</a> [Cu-64 DOTATATE] integrated positron emission tomography [PET]/computed tomography [CT] scan), and assay for blood and/or urine tumor markers in patients who have clinical symptoms or signs of a functioning tumor:</p><p class="bulletIndent1"><span class="glyph">●</span>CT may identify a primary site in the lungs, gastrointestinal tract, or pancreas.</p><p></p><p class="bulletIndent1">Mesenteric masses are usually indicative of a primary tumor located in the small intestine. Most metastatic NET patients whose scans feature a typical-appearing mesenteric mass  (<a class="graphic graphic_diagnosticimage graphicRef72556" href="/z/d/graphic/72556.html" rel="external">image 1</a>) can be presumptively considered to have a small intestinal primary and should be treated according to guidelines for metastatic small intestinal NETs. (See  <a class="medical medical_review" href="/z/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring", section on 'Imaging'</a>.)</p><p></p><p class="bulletIndent1">Magnetic resonance imaging (MRI) is an alternative cross-sectional imaging technique that may be preferred by some clinicians; it is more sensitive than CT for the presence of liver metastases. (See  <a class="medical medical_review" href="/z/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring", section on 'Cross-sectional imaging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 80 percent of well-differentiated NETs of unknown primary site, including pancreatic NETs (with the exception of insulinomas) and gastrointestinal NETs, have high concentrations of somatostatin receptors and can be detected using somatostatin receptor imaging.</p><p></p><p class="bulletIndent1">PET with newer somatostatin receptor-targeting radiotracers, such as <a class="drug drug_general" data-topicid="108440" href="/z/d/drug information/108440.html" rel="external">Ga-68 DOTATATE</a>, Ga-68 DOTATOC, and Cu-64 DOTATATE, is more sensitive than somatostatin receptor scintigraphy with indium-111 (111-In) pentetreotide (OctreoScan), particularly for small tumors [<a href="#rid20">20</a>]. Because of the greater sensitivity, Ga-68 DOTATATE, Ga-68 DOTATOC, or Cu-64 DOTATATE PET/CT is preferred over conventional 111-In pentetreotide scanning for identifying an occult primary site, where available [<a href="#rid21">21,22</a>]. This subject is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring", section on 'Somatostatin receptor-based imaging techniques'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a primary site cannot be identified through these imaging modalities, upper and lower endoscopy (with attention to the terminal ileum) should be performed. While video capsule endoscopy allows for evaluation of the entire small intestine, routine use of capsule endoscopy cannot be recommended due to the risk of bowel obstruction from retention of the capsule at the site of an intestinal NET [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The advent of new systemic treatment options for pancreatic NETs provides an additional impetus to identify an occult pancreatic primary site. Endoscopic ultrasonography represents the most sensitive method for identification of a primary pancreatic tumor in patients with liver metastases who are lacking evidence of a small intestinal primary (such as a mesenteric mass or symptoms of carcinoid syndrome) [<a href="#rid24">24-26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As noted above, immunohistochemical staining and/or a molecular cancer classifier assay (MCCA) performed on the diagnostic sample may be informative. As examples, positivity for <em>TTF-1</em> suggests a lung or thyroid tumor; positivity for <em>CDX2</em> suggests midgut origin; positivity for <em>PAX8</em> or <em>ISL1</em> suggests pancreatic, duodenal, or rectal origin [<a href="#rid12">12,13,17,19</a>]. However, none of these immunohistochemical stains is definitive in terms of identifying the primary site.</p><p></p><p class="bulletIndent1">The 92-gene MCCA is also useful in this setting, since this assay frequently suggests a specific NEN, even when immunohistochemical staining is not definitive [<a href="#rid14">14</a>]. (See <a class="local">'Pathologic classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have symptoms suggestive of carcinoid syndrome, elevated urinary levels of 5-hydroxyindoleacetic acid (5-HIAA) are highly specific for serotonin-producing NETs, most of which will be found in the small bowel (particularly the ileum) if the patient undergoes surgical exploration [<a href="#rid27">27-32</a>]. Otherwise, the clinical utility of biomarker testing is limited. (See  <a class="medical medical_review" href="/z/d/html/2622.html" rel="external">"Diagnosis of carcinoid syndrome and tumor localization", section on 'Biochemical testing for carcinoid syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/130551.html" rel="external">"Overview of tumor biomarkers in gastroenteropancreatic neuroendocrine tumors", section on 'Serotonin and 5-hydroxyindoleacetic acid (5-HIAA)'</a>.)</p><p></p><p class="headingAnchor" id="H7121028"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Well-differentiated NETs of unknown primary site are usually approached similarly to well-differentiated NETs of the tubular gastrointestinal tract. Depending on the clinical situation, appropriate management may include local therapy (eg, surgical exploration for resection of a suspected primary tumor, resection of hepatic metastases, nonsurgical liver-directed therapy for hepatic-predominant disease [eg, hepatic arterial embolization]) or systemic therapy (see  <a class="medical medical_review" href="/z/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion"</a> and  <a class="medical medical_review" href="/z/d/html/16638.html" rel="external">"Treatment of the carcinoid syndrome", section on 'Somatostatin-analog therapy'</a> and  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Radiolabeled somatostatin analogs'</a> and  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Everolimus'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Somatostatin analogs (long-acting <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> or <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">lanreotide</a>) should be considered for inhibition of tumor growth in patients with evidence of somatostatin receptor expression on somatostatin receptor imaging, and for control of symptoms in patients with carcinoid syndrome or other symptoms related to hormone secretion. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">Everolimus</a> can be considered for patients with progressive disease based on data from the RADIANT-4 trial, which demonstrated a significant improvement in progression-free survival (PFS) compared with placebo in patients with well-differentiated nonfunctioning NETs of the lung and gastrointestinal tract (hazard ratio [HR] 0.48, 95% CI 0.35-0.67) [<a href="#rid33">33</a>]. Thirty-six patients in this trial had NETs of unknown primary; in this small subgroup, an HR of 0.50 (95% CI 0.22-1.16) was observed. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with somatostatin receptor-expressing tumors, peptide receptor radiation therapy (PRRT) using radiolabeled somatostatin analogs such as <a class="drug drug_general" data-topicid="116519" href="/z/d/drug information/116519.html" rel="external">lutetium Lu-177 dotatate</a> represents a reasonable choice, particularly in light of the results of the NETTER1 study, which demonstrated a highly significant improvement in PFS with lutetium Lu-177 dotatate compared with high doses of long-acting <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> among patients with progressive midgut NETs (HR 0.21, 95% CI 0.13-0.34) [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The role of chemotherapy (eg, <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a>/<a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>) is debated, but it can be considered in patients with clinically aggressive tumors.</p><p></p><p class="headingAnchor" id="H5"><span class="h2">High-grade poorly differentiated neuroendocrine carcinoma</span><span class="headingEndMark"> — </span>Patients with high-grade poorly differentiated neuroendocrine carcinomas (NECs) of unknown primary typically present with widespread metastases. In addition to the liver, common metastatic sites include bone, lung, and brain. Histologic variants include small and large cell NEC (see  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a>). Small cell NECs can arise in extrapulmonary sites, such as the esophagus, cervix, prostate, and bladder. (See  <a class="medical medical_review" href="/z/d/html/4882.html" rel="external">"Extrapulmonary small cell cancer"</a> and  <a class="medical medical_review" href="/z/d/html/13930.html" rel="external">"Small cell neuroendocrine carcinoma of the cervix"</a> and  <a class="medical medical_review" href="/z/d/html/2979.html" rel="external">"Small cell carcinoma of the bladder"</a> and  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a>.)</p><p class="headingAnchor" id="H1146364"><span class="h3">Initial workup</span><span class="headingEndMark"> — </span>The initial evaluation should include cross-sectional imaging of the chest, abdomen, and pelvis (CT or MRI) [<a href="#rid35">35</a>]. Fluorodeoxyglucose (FDG)-PET scanning is a sensitive imaging modality due to the high metabolic rate of poorly differentiated NECs [<a href="#rid36">36</a>]. On the other hand, somatostatin receptor imaging is relatively insensitive and is not recommended in this setting. Brain MRI should be considered due to the high risk of central nervous system metastases [<a href="#rid36">36,37</a>].</p><p>Treatment of metastatic poorly differentiated NECs does not vary significantly based on primary site, and therefore an intensive workup to identify a primary site is not warranted.</p><p class="headingAnchor" id="H1146401"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>High response rates (approximately 66 percent) have been well documented using a platinum agent (<a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> or <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>) and <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> in patients with poorly differentiated NECs at a defined primary site. (See  <a class="medical medical_review" href="/z/d/html/4882.html" rel="external">"Extrapulmonary small cell cancer"</a> and  <a class="medical medical_review" href="/z/d/html/13930.html" rel="external">"Small cell neuroendocrine carcinoma of the cervix"</a> and  <a class="medical medical_review" href="/z/d/html/2979.html" rel="external">"Small cell carcinoma of the bladder"</a> and  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a>.)</p><p>Similar high response rates to a platinum/<a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> combination have been seen in patients with poorly differentiated NECs of unknown primary site, and this represents a standard approach [<a href="#rid2">2,35,38</a>]. In the largest published series, containing 99 patients, a response rate of 70 percent was observed with platinum/etoposide-based chemotherapy [<a href="#rid2">2</a>].</p><p>More recently, immune checkpoint inhibitors have proven useful for high-grade NEC of the skin (Merkel cell carcinoma) [<a href="#rid39">39</a>] and for some patients with small cell lung cancer [<a href="#rid40">40</a>]. Immunotherapy may therefore be useful in other high-grade NECs, but at this time, data remain limited. Programmed cell death protein 1 (PD-1) inhibitor monotherapy is associated with minimal response. Systemic treatment for high-grade poorly differentiated NEC is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4882.html" rel="external">"Extrapulmonary small cell cancer"</a> and  <a class="medical medical_review" href="/z/d/html/13930.html" rel="external">"Small cell neuroendocrine carcinoma of the cervix", section on 'Approach to recurrent or metastatic disease'</a> and  <a class="medical medical_review" href="/z/d/html/2979.html" rel="external">"Small cell carcinoma of the bladder", section on 'Metastatic disease'</a> and  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms", section on 'Metastatic disease'</a>.)</p><p class="headingAnchor" id="H2898376989"><span class="h2">High-grade well-differentiated tumors</span><span class="headingEndMark"> — </span>As noted above, a small subset of well-differentiated NENs appear well or moderately well differentiated on histologic examination, but they have a high proliferative rate (high-grade NET [NET, G3]). (See <a class="local">'Pathologic classification'</a> above.)</p><p>The optimal treatment for these patients is not established, but platinum-based regimens are generally not as effective as they are with high-grade poorly differentiated tumors. Management of these patients is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms", section on 'High-grade, well-differentiated tumors (NET G3)'</a>.)</p><p class="headingAnchor" id="H525999356"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111962.html" rel="external">"Society guideline links: Well-differentiated gastroenteropancreatic neuroendocrine tumors"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathologic classification</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies characterized by variable, but most often indolent, biologic behavior. Clinical behavior and prognosis correlate closely with histologic differentiation and grade.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The World Health Organization (WHO) classifies well-differentiated gastroenteropancreatic NETs into low-grade (G1), intermediate-grade (G2), and high-grade (G3) categories based on histologic appearance and proliferative rate (as assessed by mitotic count and/or Ki-67 labeling index)  (<a class="graphic graphic_table graphicRef122325" href="/z/d/graphic/122325.html" rel="external">table 2</a>). The clinical behavior of well-differentiated G1 and G2 tumors is generally indolent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All poorly differentiated neuroendocrine neoplasms (NENs) are G3 neuroendocrine carcinomas (NECs), with an aggressive clinical course. The clinical behavior of the rare well-differentiated G3 NET is in between these two entities. (See <a class="local">'Pathologic classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation and origin</strong> – Most well-differentiated NETs of unknown primary site present with liver metastases. In some patients, the primary site is subsequently identified in the intestinal tract or the pancreas. Patients with mesenteric masses on imaging scans and no evidence of disease on upper or lower endoscopy can be considered to have small intestinal primary tumors and should be treated according to guidelines for small intestinal NETs. (See <a class="local">'Clinical presentation and primary sites'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Well-differentiated tumors</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The initial evaluation should include cross-sectional imaging, usually with multiphase CT, and somatostatin receptor imaging to assist with primary localization. Where available, <a class="drug drug_general" data-topicid="108440" href="/z/d/drug information/108440.html" rel="external">gallium Ga-68 DOTATATE</a>, Ga-68 DOTATOC, or <a class="drug drug_general" data-topicid="129471" href="/z/d/drug information/129471.html" rel="external">copper Cu-64 DOTATATE</a> positron emission tomography (PET)/CT is preferred over somatostatin receptor scintigraphy (OctreoScan) because of its greater sensitivity.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If a primary site cannot be identified through these imaging modalities, upper and lower endoscopy (with attention to the terminal ileum) should be performed. Immunohistochemical stains and a 92-gene molecular cancer classifier assay (MCCA) may help in determining the tissue of origin. Endoscopic ultrasonography can be used to rule out an occult pancreatic primary tumor. (See <a class="local">'Initial workup'</a> above.)</p><p></p><p class="bulletIndent3">If a primary site still cannot be identified, we recommend that these patients be managed like those with metastatic well-differentiated nonpancreatic NETs (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who have symptoms suggestive of carcinoid syndrome, elevated urinary levels of 5-hydroxyindoleacetic acid (5-HIAA) are highly specific for serotonin-producing NETs (eg, those arising in the small bowel). (See  <a class="medical medical_review" href="/z/d/html/2622.html" rel="external">"Diagnosis of carcinoid syndrome and tumor localization", section on 'Biochemical testing for carcinoid syndrome'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Poorly differentiated tumors</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with poorly differentiated NECs generally have biologically aggressive tumors. Most either present with or rapidly develop disseminated disease. The initial evaluation should include cross-sectional imaging of the chest, abdomen, and pelvis (CT or MRI) and fluorodeoxyglucose (FDG)-PET scanning. (See <a class="local">'Initial workup'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We recommend first-line treatment with <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> or <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> combined with <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, following treatment guidelines for small and large cell NECs of the lung (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High-grade well-differentiated tumors</strong> – A subset of G3 NENs have a high proliferative rate but appear well or moderately well differentiated on histologic examination (NET, G3). The optimal treatment for these patients is not established, but platinum-based regimens are generally not as effective as they are with poorly differentiated tumors, which are all high-grade. Management of these patients is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms", section on 'High-grade, well-differentiated tumors (NET G3)'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rassy E, Pavlidis N. The currently declining incidence of cancer of unknown primary. Cancer Epidemiol 2019; 61:139.</a></li><li><a class="nounderline abstract_t">Spigel DR, Hainsworth JD, Greco FA. Neuroendocrine carcinoma of unknown primary site. Semin Oncol 2009; 36:52.</a></li><li><a class="nounderline abstract_t">Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5:1502.</a></li><li><a class="nounderline abstract_t">Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25:458.</a></li><li><a class="nounderline abstract_t">Strosberg JR, Nasir A, Hodul P, Kvols L. Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res 2008; 2:113.</a></li><li><a class="nounderline abstract_t">Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26:3063.</a></li><li><a class="nounderline abstract_t">Catena L, Bichisao E, Milione M, et al. Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms? Tumori 2011; 97:564.</a></li><li><a class="nounderline abstract_t">Scoazec JY, Couvelard A, Monges G, et al. Professional Practices and Diagnostic Issues in Neuroendocrine Tumour Pathology: Results of a Prospective One-Year Survey Among French Pathologists (the PRONET Study). Neuroendocrinology 2016.</a></li><li class="breakAll">Klimstra DS, Kloppell G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.16.</li><li><a class="nounderline abstract_t">Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Intern Med 1988; 109:364.</a></li><li><a class="nounderline abstract_t">Riihimäki M, Hemminki A, Sundquist K, et al. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer 2016; 139:2679.</a></li><li><a class="nounderline abstract_t">Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry. Adv Anat Pathol 2013; 20:285.</a></li><li><a class="nounderline abstract_t">Maxwell JE, Sherman SK, Stashek KM, et al. A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors. Surgery 2014; 156:1359.</a></li><li><a class="nounderline abstract_t">Kerr SE, Schnabel CA, Sullivan PS, et al. A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors. Mod Pathol 2014; 27:44.</a></li><li><a class="nounderline abstract_t">La Rosa S, Chiaravalli AM, Placidi C, et al. TTF1 expression in normal lung neuroendocrine cells and related tumors: immunohistochemical study comparing two different monoclonal antibodies. Virchows Arch 2010; 457:497.</a></li><li><a class="nounderline abstract_t">Oien KA. Pathologic evaluation of unknown primary cancer. Semin Oncol 2009; 36:8.</a></li><li><a class="nounderline abstract_t">Heverhagen AE, Geis C, Fendrich V, et al. Embryonic transcription factors CDX2 and Oct4 are overexpressed in neuroendocrine tumors of the ileum: a pilot study. Eur Surg Res 2013; 51:14.</a></li><li><a class="nounderline abstract_t">La Rosa S, Rigoli E, Uccella S, et al. CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors. Virchows Arch 2004; 445:248.</a></li><li><a class="nounderline abstract_t">Sangoi AR, Ohgami RS, Pai RK, et al. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Mod Pathol 2011; 24:412.</a></li><li><a class="nounderline abstract_t">Sadowski SM, Neychev V, Millo C, et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol 2016; 34:588.</a></li><li><a class="nounderline abstract_t">Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med 2018; 59:66.</a></li><li><a class="nounderline abstract_t">Crown A, Rocha FG, Raghu P, et al. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors. J Surg Oncol 2020; 121:480.</a></li><li><a class="nounderline abstract_t">Strosberg JR, Shibata D, Kvols LK. Intermittent bowel obstruction due to a retained wireless capsule endoscope in a patient with a small bowel carcinoid tumour. Can J Gastroenterol 2007; 21:113.</a></li><li><a class="nounderline abstract_t">Khashab MA, Yong E, Lennon AM, et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc 2011; 73:691.</a></li><li><a class="nounderline abstract_t">Rösch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992; 326:1721.</a></li><li><a class="nounderline abstract_t">Anderson MA, Carpenter S, Thompson NW, et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000; 95:2271.</a></li><li><a class="nounderline abstract_t">Bergsland EK, Nakakura EK. Neuroendocrine tumors of unknown primary: is the primary site really not known? JAMA Surg 2014; 149:889.</a></li><li><a class="nounderline abstract_t">Boudreaux JP, Putty B, Frey DJ, et al. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg 2005; 241:839.</a></li><li><a class="nounderline abstract_t">Wang SC, Parekh JR, Zuraek MB, et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg 2010; 145:276.</a></li><li><a class="nounderline abstract_t">Massimino KP, Han E, Pommier SJ, Pommier RF. Laparoscopic surgical exploration is an effective strategy for locating occult primary neuroendocrine tumors. Am J Surg 2012; 203:628.</a></li><li><a class="nounderline abstract_t">Bartlett EK, Roses RE, Gupta M, et al. Surgery for metastatic neuroendocrine tumors with occult primaries. J Surg Res 2013; 184:221.</a></li><li><a class="nounderline abstract_t">Wang YZ, Chauhan A, Rau J, et al. Neuroendocrine tumors (NETs) of unknown primary: is early surgical exploration and aggressive debulking justifiable? Chin Clin Oncol 2016; 5:4.</a></li><li><a class="nounderline abstract_t">Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387:968.</a></li><li><a class="nounderline abstract_t">Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017; 376:125.</a></li><li><a class="nounderline abstract_t">Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95:157.</a></li><li><a class="nounderline abstract_t">Hicks RJ. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Cancer Imaging 2010; 10 Spec no A:S83.</a></li><li><a class="nounderline abstract_t">Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 2010; 39:799.</a></li><li><a class="nounderline abstract_t">Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006; 24:3548.</a></li><li><a class="nounderline abstract_t">Colunga A, Pulliam T, Nghiem P. Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes. Clin Cancer Res 2018; 24:2035.</a></li><li><a class="nounderline abstract_t">Horn L, Reck M, Spigel DR. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. Oncologist 2016; 21:910.</a></li></ol></div><div id="topicVersionRevision">Topic 4876 Version 51.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31254795" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The currently declining incidence of cancer of unknown primary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19179188" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Neuroendocrine carcinoma of unknown primary site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2443618" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Karnofsky memorial lecture. An odyssey in the land of small tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15180952" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The diagnosis and medical management of advanced neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19259290" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Biology and treatment of metastatic gastrointestinal neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18565894" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22158484" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27442514" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Professional Practices and Diagnostic Issues in Neuroendocrine Tumour Pathology: Results of a Prospective One-Year Survey Among French Pathologists (the PRONET Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27442514" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Professional Practices and Diagnostic Issues in Neuroendocrine Tumour Pathology: Results of a Prospective One-Year Survey Among French Pathologists (the PRONET Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2841895" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27553864" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The epidemiology of metastases in neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23939147" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25456909" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23846576" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20694477" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : TTF1 expression in normal lung neuroendocrine cells and related tumors: immunohistochemical study comparing two different monoclonal antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19179185" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pathologic evaluation of unknown primary cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23887079" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Embryonic transcription factors CDX2 and Oct4 are overexpressed in neuroendocrine tumors of the ileum: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15517368" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20890270" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26712231" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29025982" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31853990" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299616" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Intermittent bowel obstruction due to a retained wireless capsule endoscope in a patient with a small bowel carcinoid tumour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21067742" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1317506" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Localization of pancreatic endocrine tumors by endoscopic ultrasonography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11007228" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25029597" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Neuroendocrine tumors of unknown primary: is the primary site really not known?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15912033" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Surgical treatment of advanced-stage carcinoid tumors: lessons learned.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231629" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Identification of unknown primary tumors in patients with neuroendocrine liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22459446" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Laparoscopic surgical exploration is an effective strategy for locating occult primary neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23643298" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Surgery for metastatic neuroendocrine tumors with occult primaries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26932428" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Neuroendocrine tumors (NETs) of unknown primary: is early surgical exploration and aggressive debulking justifiable?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26703889" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28076709" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22262022" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20880795" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664477" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16877720" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29217527" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27354668" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
